

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Use of 5-HT<sub>2</sub> receptor antagonists and physiologically acceptable salts and solvates thereof for the preparation of a medicament for extending both non-REM sleep and REM sleep.
2. (Original) Use according to Claim 1, characterised in that the 5-HT<sub>2</sub> receptor antagonists are of the 5-HT<sub>2a</sub> sub-type.
3. (Original) Use of 5-HT<sub>2a</sub> receptor antagonists according to Claim 2, selected from a group consisting of
  - (a) (3-aminocarbonyl-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone,
  - (b) (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone and physiologically acceptable salts and solvates thereof for the preparation of a medicament for extending both non-REM sleep and REM sleep.
4. (Original) Use of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone and physiologically acceptable salts and solvates thereof for the preparation of a medicament for extending both non-REM sleep and REM sleep.
5. (Currently Amended) Use of 5-HT<sub>2</sub> receptor antagonists and physiologically acceptable salts and solvates thereof according to claim 1 one or more of Claims 1 to 4 for the preparation of a medicament for the treatment of difficulties in falling asleep and staying asleep and premature awakening in the morning.
6. (Currently Amended) Use of 5-HT<sub>2</sub> receptor antagonists and physiologically acceptable salts and solvates thereof according to claim 1 one or more of Claims 1 to 5 in combination with one or more further sleeping drugs.